Peptides for gut inflammation FAQ

Discard the vial and obtain a new one. Do not use it. Once reconstituted peptides exceed 8°C for more than two hours, protein denaturation begins. The peptide loses its tertiary structure, meaning it can no longer bind to target receptors in the gut mucosa. There's no salvaging it through re-refrigeration. Temperature excursions are cumulative: even if the vial was only at room temperature for six hours, that's enough to compromise potency by 40–70%.

Verify that the oral peptide is enteric-coated. Uncoated peptides degrade in gastric acid within 15–20 minutes, meaning they never reach the small intestine intact. Gastric pH (1.5–3.5) cleaves peptide bonds, fragmenting the chain into individual amino acids that have no therapeutic activity. Enteric-coated capsules dissolve only at pH 5.5 or higher, which occurs in the duodenum. If your oral peptide isn't enteric-coated, switch to subcutaneous administration or source an enteric-coated version.

Rotate injection sites and verify reconstitution technique. Subcutaneous inflammation. Redness, swelling, tenderness at the injection site. Usually indicates one of three issues: injecting too quickly (which causes tissue trauma), using a needle that's too large (26-gauge or smaller is standard for peptides), or bacterial contamination from improper reconstitution. Always use a fresh alcohol swab to sterilise the vial stopper before each draw, and never reuse needles. If inflammation persists despite correct technique, the peptide may contain aggregates from improper storage. Contact your supplier.

Oral KPV in enteric-coated capsules achieves 30–35% bioavailability. Sufficient for localised GI tract effects but inadequate for systemic anti-inflammatory action. BPC-157 tolerates oral administration better than most peptides due to its cyclic structure, and published protocols use 500 mcg oral doses twice daily. Thymosin Alpha-1 cannot be taken orally. It degrades completely in gastric acid and must be injected subcutaneously. If injection is not viable, BPC-157 is the only peptide with meaningful oral efficacy.

Unreconstituted lyophilised powder tolerates ambient temperature (up to 25°C) for 24–48 hours without significant degradation. Return it to refrigeration immediately and it remains usable. Reconstituted peptide solutions exposed to temperatures above 8°C for more than 4 hours undergo protein denaturation that cannot be reversed. Visual clarity is not a reliable indicator. Denatured peptides often remain clear and colourless. Discard any reconstituted vial exposed to temperature excursion and prepare a fresh solution.

Start with KPV if your disease involves active mucosal inflammation with elevated fecal calprotectin or CRP. The NF-κB inhibition targets the inflammatory cascade directly. BPC-157 becomes relevant if you have structural complications (fistulas, strictures, or post-surgical healing needs). Thymosin Alpha-1 is appropriate when systemic markers (persistent lymphocytosis, elevated IL-6) indicate immune dysregulation beyond localised GI inflammation. Peptide selection without biomarker context is guesswork.

Oral administration requires 3–5× higher doses to achieve equivalent tissue exposure, and the capsules must be enteric-coated to survive gastric acid. Standard gelatin capsules disintegrate at pH 2.0, releasing the peptide into the stomach where pepsin and gastric acid degrade it within 15–30 minutes. Enteric-coated capsules delay release until the small intestine (pH 6.5–7.5), where peptide absorption is possible but still limited by brush-border peptidases. If you're taking 500mcg BPC-157 subcutaneously, the oral equivalent is roughly 1500–2500mcg in enteric-coated form. Measure efficacy objectively. If fecal calprotectin or symptom scores don't improve within 3 weeks on oral dosing, switch to subcutaneous administration.

Discard the vial immediately. Cloudiness indicates either bacterial contamination (if bacteriostatic water wasn't used) or protein aggregation from temperature excursion. Injecting a contaminated or aggregated solution creates infection risk and delivers zero therapeutic benefit. Aggregated peptides lose their receptor-binding capability entirely. This is why proper storage at 2–8°C and sterile reconstitution technique are non-negotiable. If cloudiness develops within 7 days, review your storage conditions and reconstitution process before preparing the next vial.

Resume dosing immediately at your standard dose. Do not double-dose to compensate. Missing 48 hours during an active inflammatory flare may allow cytokine levels to rebound slightly, but the peptide's anti-inflammatory effect reestablishes within 24–48 hours of resuming administration. If you're using BPC-157 for mucosal repair, two missed doses represents roughly 10% of a 4-week protocol. The overall repair trajectory remains intact as long as you complete the remaining scheduled doses. The bigger risk is inconsistent dosing across multiple weeks, which prevents the peptide from maintaining steady-state tissue concentrations required for sustained NF-κB suppression or angiogenesis signaling.